"Men"

Recently, the European Commission has approved cemiplimab-rwlc (Libtayo), manufactured by US-based Regeneron, as a monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer whose disease has progressed during or after platinum-containing chemotherapy. The results of the trial showed that this therapy significantly improved patient survival and had a good safety profile.

Pfizer's new treatment, Elranatamab, has received Breakthrough Therapy designation from the FDA for the treatment of patients with relapsed or refractory multiple myeloma. Data from the trial showed a patient efficacy rate of 61.0% and that once the therapy is effective, efficacy is maintained for more than six months in over 90% of patients!

Data from a trial show that adding the new drug Eganelisib to standard treatment significantly improves the length of survival for patients with triple-negative breast cancer whose disease remains unexacerbated. Patients benefited regardless of their PD-L1 status.

New research by japanese scientists has found that

As medicine continues to advance, there are many good drugs and options to fight cancer. Just recently, a study showed that the NALIRIFOX regimen significantly improved the overall survival of patients with advanced pancreatic ductal adenocarcinoma who had not received previous treatment.

Researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have now identified a new treatment that promises to help cancer patients with bone marrow transplants manage side effects better than current standard therapies, making the treatment more effective and safer.

Prostate cancer, which has been increasing in incidence worldwide in recent years, is now a more common cancer among Japanese men. Often, patients with prostate cancer have a poor prognosis and poor survival once they have developed multiple recurrent metastases after treatment with hormones and are difficult to treat with conventional radiotherapy.

Warning: If you have 4 symptoms in your eye, don't take them seriously, they are precursors to retinal detachment

There is an urgent clinical need for new antimicrobial drugs to break through the dilemma of cIAI treatment in children and address the growing challenge of drug resistance.

Approval for new FIC depression drug on the horizon!